Welcome : Guest

INTRAVENOUS (IV) IRON DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 21 companies including many key and niche players such as -

Allergan Plc
AMAG Pharmaceuticals, Inc.
Daiichi Sankyo, Inc.
Luitpold Pharmaceuticals, Inc.
Pharmacosmos A/S
Sanofi US

Click here to request a full list of companies covered in the report...

Code: MCP-6464
Price: $4950
Companies: 21
Pages: 165
Date: September 2017
Market Data Tables: 77
  Status: * New Report



TABLE OF CONTENTS


  INTRAVENOUS (IV) IRON DRUGS (Complete Report) Pages : 165   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Iron Deficiency Anemia (IDA) – An Overview.....II-1 1$100
   Table 1: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN) (includes corresponding Graph/Chart).....II-2
Intravenous (IV) Iron Drugs Market – A Quick Primer.....II-2
1$350
   Table 2: Intravenous Iron Drugs Market by Therapeutic Area: 2016 (includes corresponding Graph/Chart).....II-31$350
   US and Europe Dominate IV Iron Market.....II-4
Asia-Pacific – The Fastest Growing Market.....II-4
1$100
   Leading Intravenous Iron Drugs Globally.....II-5
Leading IV Iron Drugs Available in the Market.....II-5
1$100
   Leading Intravenous Iron Drugs: In a Nutshell.....II-61$100
   Ferinject/Injectafer – The Leading Intravenous Iron Drug Globally.....II-7 1$100
   Table 3: Worldwide Ferinject (Injectafer) Sales (in US$ Million): 2014-2017 (First Half) (includes corresponding Graph/Chart).....II-8
Venofer® – Looses Ground to Ferinject.....II-8
1$350
   Table 4: Worldwide Venofer Sales (In US$ Million): 2014-2017 (First Half) (includes corresponding Graph/Chart).....II-9
Feraheme Obtains Broader Label Approval.....II-9
Table 5: Worldwide Feraheme Sales (in US$ Million): 2014-2017 (First Half) (includes corresponding Graph/Chart).....II-9
Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering
  from IDA.....II-9
1$350
   Gluconate (Ferrlecit® and Nulecit).....II-10
Dextran.....II-10
Global Market Leaders.....II-10
1$100
   Expanding Pool of ESRD and CKD Patients – The Major Growth Driver for Intravenous (IV)
  Iron Drugs.....II-11
ESRD Prevalence Statistics: An Opportunity Indicator.....II-11
1$100
   Table 6: Increasing Number of ESRD Patients Worldwide: 2014-2018 (includes corresponding Graph/Chart).....II-12

Table 7: ESRD Prevalence in Select Countries (2015): Number of ESRD Patients Per Million Population in EU-28, Japan, Taiwan, USA and Global (includes corresponding Graph/Chart).....II-12
1$350
   Table 8: Global Population of ESRD Patients Undergoing Treatment by Type of Modality (2010, 2015 & 2020P): Percentage Breakdown of Patients Undergoing Dialysis Therapy, and Kidney Transplantation (includes corresponding Graph/Chart).....II-13
Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market.....II-13
1$350
   Table 9: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart).....II-14
Dialysis Patients – A Major Market for Intravenous Iron Supplements.....II-14
1$350
   Table 10: Worldwide Distribution of Dialysis Patients by Geographic Region (2016): Percentage Breakdown of Patient Population (includes corresponding Graph/Chart).....II-151$350
   Table 11: Global Population of Kidney Dialysis Patients by Type of Treatment Modality (2016): Percentage Breakdown of Patients Receiving Hemodialysis, Home Hemodialysis, and Peritoneal Dialysis (includes corresponding Graph/Chart).....II-16
Ageing Population Drives Demand for IV Iron Drugs.....II-16
1$350
   Table 12: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart).....II-171$350
   Table 13: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart).....II-181$350
   Table 14: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart).....II-191$350
   Table 15: Life Expectancy for Select Countries in Number of Years: 2015 (includes corresponding Graph/Chart).....II-20
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs.....II-20
1$350
   Comparison of Ferrous Salts with IV Iron Therapy.....II-211$100
   Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs.....II-22
Anemia in Heart Failure – A Market with Huge Potential.....II-22
1$100
   Table 16: Number of AHF Events in the US and EU by Type: 2017E (includes corresponding Graph/Chart).....II-23
Chemotherapy Induced Anemia to Promote IV Iron Supplements.....II-23
Table 17: Worldwide Incidence of Cancer: Number of New Cases Diagnosed for the Years 2013, 2020 & 2030 (includes corresponding Graph/Chart).....II-23
1$350
   Table 18: New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart).....II-24
Correction of IDA in Pregnancy Signals Opportunities.....II-24
1$350
   Women’s Health – A Key Growth Opportunity.....II-25
Perioperative and Postoperative Anemia – A Niche Market Beckons.....II-25
1$100
   Adverse Reactions of IV Iron Preparations Raise Concerns.....II-26
Dosing Limitations Plague IV Iron Market.....II-26
1$100
   Select Therapeutic Areas and the Required Iron Doses.....II-271$100
   Increasing Trend towards Bundled Reimbursements.....II-28
A Glimpse of Regulations in the US and Europe.....II-28
1$100
   Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron
  Drugs.....II-29
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across
  Belgium, Germany, Netherlands, the UK, France, the US and Ontario,
    Canada.....II-29
1$100
   Iron – A Vital Element.....II-30
Iron-Deficiency Anemia.....II-30
Intravenous Therapy.....II-30
Patients of Chronic Illnesses, the Elderly and Women – The High Risk
  Population.....II-30
1$100
   Treatment for Iron Deficiency Anemia.....II-311$100
   Iron Requirement in Chronic Kidney Disease.....II-32
Classification of Iron Deficiency in CKD.....II-32
Treating Iron Deficiency in CKD Patients.....II-32
Side Effects of Iron Supplementation in CKD.....II-32
1$100
   Methods of Restoring Iron.....II-33
Oral Iron Therapy.....II-33
1$100
   IV Iron-Infusion Therapy.....II-34
Intravenous (IV) Iron.....II-34
1$100
   Conditions for Receiving Iron Injections.....II-35
Injection Procedure.....II-35
1$100
   Categories of Iron Injections.....II-361$100
   Suitability of IV Iron Preparation.....II-37
Suitability of Regimen.....II-37
1$100
   Management of Iron Doses.....II-38
Effectiveness of Iron Injection.....II-38
Requirement of Test Dose.....II-38
Adverse Effects of Iron Injections.....II-38
1$100
   Iron Therapy: Caution.....II-39
Duration of Iron Infusion.....II-39
Iron Overdose.....II-39
Iron-Out-of-Balance Therapies.....II-39
Blood Donation.....II-39
1$100
   Therapeutic Phlebotomy.....II-40
Red Cell Apheresis.....II-40
Iron Chelation Therapy.....II-40
Iron-Chelating Drugs.....II-40
1$100
   Desferrioxamine or Desferal.....II-41
Deferiprone or Ferriprox.....II-41
Conditions for Undergoing Iron Chelation Therapy.....II-41
Kinds of Chelation Therapy.....II-41
1$100
   Side Effects Caused by IV Iron Chelation.....II-421$100
   AMAG to Expand Feraheme® Label.....II-43
Pharmacosmos and Laboratoire Aguettant to Commercialize Monover® in France.....II-43
Pharmacosmos and Pfizer to Commercialize Monover® in Brazil.....II-43
Rockwell Medical Announces Data Presentation on Triferic Intravenous (IV)
  Administration.....II-43
Nippon Shinyaku and Pharmacosmos to Develop and commercialize Monofer® in
  Japan.....II-43
1$100
   Lupin Announces the Launch of Novel Injectable Iron Formulation in India.....II-44
Pharmacosmos and Pfizer to Commercialize Monofer® in Canada.....II-44
1$100
   Allergan Plc. (Ireland).....II-45
AMAG Pharmaceuticals, Inc. (USA).....II-45
1$100
   Daiichi Sankyo, Inc. (USA).....II-46
Luitpold Pharmaceuticals, Inc. (USA).....II-46
American Regent, Inc. (USA).....II-46
1$100
   Pharmacosmos A/S (Denmark).....II-47
Sanofi US (USA).....II-47
Vifor Pharma Ltd. (Switzerland).....II-47
1$100
   Vifor Fresenius Medical Care Renal Pharma (Switzerland).....II-481$100
   Table 19: World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-491$350
   Table 20: World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-501$350
   Table 21: World 14-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-511$350
   A. Market Analysis.....III-1
United States: The Largest Market for Intravenous Iron Drugs Globally.....III-1
1$75
   Table 22: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Share of Patients with ID and IDA for Select Diseases (includes corresponding Graph/Chart).....III-21$200
   Rising Incidence of ESRD Drives IV Iron Drugs Market.....III-3
ESRD Incidence and Prevalence Statistics: Opportunity Indicators.....III-3
Table 23: Reported Incidence of ESRD in the US (2010-2013): Breakdown by Age (includes corresponding Graph/Chart).....III-3
1$200
   Table 24: Reported Incidence of ESRD in the US (2010-2013): Breakdown by Gender (includes corresponding Graph/Chart).....III-4

Table 25: Reported Incidence of ESRD in the US (2010-2013): Breakdown by Race (includes corresponding Graph/Chart).....III-4
1$200
   Table 26: Reported Incidence of ESRD in the US (2010-2013): Breakdown by Ethnicity (includes corresponding Graph/Chart).....III-5

Table 27: Reported Incidence of ESRD in the US (2010-2013): Breakdown by Cause.....III-5

Table 28: Reported Prevalence of ESRD in the US (2010-2013): Breakdown by Gender (includes corresponding Graph/Chart).....III-5
1$200
   Table 29: Reported Prevalence of ESRD in the US (2010-2013): Breakdown by Race (includes corresponding Graph/Chart).....III-6

Table 30: ESRD Treatment in the US by Type (2016): Percentage Share Breakdown of Number of Patients Treated for Hemodialysis, Peritoneal Dialysis, and Transplant (includes corresponding Graph/Chart).....III-6
Aging Demographics: A Key Market Driver.....III-6
1$200
   Table 31: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart).....III-7
Injectafer – The Leading Intravenous Iron Drug in the US.....III-7
1$200
   Addressing Broader IDA Indications Present Opportunities.....III-8
Table 32: The US Non-Dialysis IV Iron Drugs Market in Volume Terms: 2016 (includes corresponding Graph/Chart).....III-8
CMS Reimbursement Shifts to Bundled Payment for Dialysis.....III-8
1$200
   Medicare Coverage of Dialysis Treatment for ESRD Patients.....III-9
CMS Introduces New Bundled Payment – ESRD Prospective Payment System (PPS).....III-9
1$75
   CMS Updates Policies and Payment Bundle for ESRD for CY 2016.....III-101$75
   Impact of Changes in Payment System for CMS and Service Providers.....III-11
Concerns over Allergic Reactions Prompt FDA to Issue Warning.....III-11
1$75
   Potential Short-Term and Long-Term Safety Concerns of IV Iron
  Preparations.....III-12
FDA Issues Drug Safety Communication for Feraheme or Ferumoxytol.....III-12
1$75
   Strategic Corporate Developments.....III-13
Select Key Players.....III-13
3$225
   B. Market Analytics.....III-16
Table 33: The US Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-16
1$200
   Table 34: The US Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-171$200
   A. Market Analysis.....III-18
Table 35: Canadian Dialysis Patient Population: 2014-2018 (includes corresponding Graph/Chart).....III-18
Strategic Corporate Development.....III-18
1$200
   B. Market Analytics.....III-19
Table 36: Canadian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-19
1$200
   Table 37: Canadian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-201$200
   A. Market Analysis.....III-21
Current & Future Analysis.....III-21
Table 38: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart).....III-21

Table 39: Dialysis Patient Population in Japan (2014-2018) (includes corresponding Graph/Chart).....III-21
1$200
   Bundled Payment Policy Encourages IV Iron Use.....III-22
Strategic Corporate Development.....III-22
1$75
   B. Market Analytics.....III-23
Table 40: Japanese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-23
1$200
   Table 41: Japanese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Current & Future Analysis.....III-25
European Authorities Recommends Ferinject for Iron Deficiency in Systolic Heart
  Failure Patients.....III-25
Research Thrusts IV Iron Therapies into Limelight.....III-25
List of Available IV Iron Drugs in Europe.....III-25
1$75
   Ageing Population Boosts Demand.....III-26
Table 42: European Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-26
1$200
   Table 43: European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart).....III-271$200
   Strategic Corporate Development.....III-28
B. Market Analytics.....III-28
Table 44: European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-28
1$200
   Table 45: European Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-291$200
   Table 46: European 14-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-301$200
   Market Analysis.....III-31
Table 47: French Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-31
1$200
   Table 48: French Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-321$200
   A. Market Analysis.....III-33
Current & Future Analysis.....III-33
Fresenius Medical Care AG & Co. Kgaa – A Key Player.....III-33
1$75
   B. Market Analytics.....III-34
Table 49: German Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-34
1$200
   Table 50: German Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-351$200
   Market Analysis.....III-36
Table 51: Italian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-36
1$200
   Table 52: Italian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-371$200
   Market Analysis.....III-38
Table 53: UK Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-38
1$200
   Table 54: UK Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-391$200
   Market Analysis.....III-40
Table 55: Spanish Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-40
1$200
   Table 56: Spanish Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   Market Analysis.....III-42
Table 57: Russian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-42
1$200
   Table 58: Russian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-431$200
   A. Market Analysis.....III-44
Current & Future Analysis.....III-44
Key Players.....III-44
2$150
   B. Market Analytics.....III-46
Table 59: Rest of European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-46
1$200
   Table 60: Rest of European Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-471$200
   A. Market Analysis.....III-48
India & China Offer Significant Growth Opportunities.....III-48
Table 61: China and India Lead Global Population (2015): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Millions) by Age Group (includes corresponding Graph/Chart).....III-48
1$200
   Dialysis Modality Preferences.....III-49
Table 62: Asia-Pacific Dialysis Patient Population (2014-2018) (includes corresponding Graph/Chart).....III-49
Dialysis Patient Population by Modality.....III-49
Table 63: Dialysis Patient Population by Modality in Select Asia-Pacific Countries (2016) (includes corresponding Graph/Chart).....III-49
1$200
   B. Market Analytics.....III-50
Table 64: Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-50
1$200
   Table 65: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-511$200
   Table 66: Asia-Pacific 14-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-521$200
   Market Analysis.....III-53
Table 67: Chinese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-53
1$200
   Table 68: Chinese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-541$200
   A. Market Analysis.....III-55
Product Launch.....III-55
B. Market Analytics.....III-55
Table 69: Indian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-55
1$200
   Table 70: Indian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-561$200
   Market Analysis.....III-57
Table 71: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-57
1$200
   Table 72: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-581$200
   A. Market Analysis.....III-59
Current & Future Analysis.....III-59
Strategic Corporate Development.....III-59
1$75
   B. Market Analytics.....III-60
Table 73: Latin American Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-60
1$200
   Table 74: Latin American Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-611$200
   Table 75: Latin American 14-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-621$200
   A. Market Analysis.....III-63
Current & Future Analysis.....III-63
B. Market Analytics.....III-63
Table 76: Rest of World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-63
1$200
   Table 77: Rest of World Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-641$200
  
Total Companies Profiled: 21 (including Divisions/Subsidiaries - 22)

Region/Country Players

The United States 5 Japan 2 Europe 7 France 1 Germany 1 The United Kingdom 1 Rest of Europe 4 Asia-Pacific (Excluding Japan) 8
Click here to request a full table of contents and more details on this project.